Cor Vasa 2018, 60(3):e327-e330 | DOI: 10.1016/j.crvasa.2017.05.013

Takotsubo cardiomyopathy in a patient with essential thrombocythemia treated with anagrelide: Case report

Lenka Eremiášová^*, Josef Marek, Tomáš Paleček, Aleš Král, Michael Aschermann, Aleš Linhart, Vilém Danzig

II. interní klinika kardiologie a angiologie, Kardiovaskulární centrum, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika

Takotsubo cardiomyopathy is a rare syndrome. Most often imitates acute coronary syndrome. It is characterized by transient wall motion abnormalities, especially in the apical segments of the left ventricle. Less frequently it is possible to find transient akinesis or dyskinesis in the mid-ventricular segments of the left ventricle. Pathophysiological mechanisms are not completely clear. The main cause of stress cardiomyopathy is stress insult. But in rare cases takotsubo cardiomyopathy can be caused by other conditions. We reported a rare case of takotsubo cardiomyopathy caused by high dose anagrelide therapy. Anagrelide is most often used in patients with thrombocythemia. It belongs to phosphodiesterase III inhibitors and through specific pathways has certain effects on myocardium. It is the first case of takotsubo cardiomyopathy resulting from anagrelide therapy in the Czech Republic.

Keywords: Anagrelide; Left ventricle; Phosphodiesterase III inhibitor; Takotsubo cardiomyopathy; Thrombocythemia

Received: December 20, 2016; Accepted: May 20, 2017; Published: June 1, 2018  Show citation